Sientra to Report First Quarter 2021 Financial Results on May 11, 2021

Rhea-AI Summary

Sientra (NASDAQ: SIEN) will release its first-quarter 2021 financial results on May 11, 2021, after market close, with a conference call scheduled for 4:30 p.m. ET. The company specializes in medical aesthetics, particularly products for plastic surgeons, including FDA-approved breast implants and the miraDry system for sweat and hair reduction. A live webcast of the call will be accessible on Sientra's website, where important investor information is also routinely posted.

Positive

• Sientra's products include the first fifth generation breast implants approved by the FDA for sale in the U.S.
• Sientra's miraDry system is FDA-cleared for permanent underarm sweat and hair reduction.

Negative

• None.

SANTA BARBARA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 11, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 3087322.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Investor Relations Contact
Leigh Salvo
Leigh@gilmartinir.com 

FAQ

When will Sientra report its Q1 2021 financial results?

Sientra will release its Q1 2021 financial results on May 11, 2021.

What are Sientra's main products?

Sientra's main products include breast implants, the Allox2 breast tissue expander, and the miraDry system.

How can I listen to Sientra's financial results conference call?

You can listen to Sientra's financial results conference call live on their Investor Relations website.

What is the ticker symbol for Sientra?

Sientra's ticker symbol is SIEN.

What time is Sientra's conference call on May 11, 2021?

Sientra's conference call on May 11, 2021, is scheduled for 4:30 p.m. Eastern Time.